CAS: 7542-37-2; (2S,3S,4R,5R,6R)-5-Amino-2-(Aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-Diamino-2-(((2S,3R,4R,5S,6R)-3-Amino-4,5-Dihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-6-Hydroxycyclohexyl)Oxy)-4-Hydroxy-2-(Hydroxymethyl)Tetrahydrofuran-3-yl)Oxy)Tetrahydro-2H-Pyran-3,4-Diol

该化合物是一种主要用于治疗某些寄生虫和细菌所造成感染的寄生虫病抗生素,主要用于治疗某些寄生虫和细菌的寄生虫病,来源于细菌链球菌,对利什曼病和羊膜虫病等原生虫感染特别有效.帕罗莫米辛工作与细菌的30S 脊髓膜炎亚细胞结合,抑制蛋白合成,最终导致细菌细胞死亡.该化合物的特点是其毒性相对较低,与其他微粒细胞表面相比,适合特定人群使用,包括孕妇进行某些感染.帕罗莫米辛通常通过口服或肌肉内施用,取决于正在治疗的条件.在水中的溶液使得各种药物制剂易于配方.然而,重要的是监测潜在的副作用,包括胃肠炎和肾中毒,特别是在有前肾病的病人中.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      📜Paromomycin Sulfate置于amberlist Ira 400 Oh(-)体系中,化学反应生成 巴龙霉素
      参考文献:Synthesis Of Multifunctional Pamam-aminoglycoside Conjugates With Enhanced Transfection Efficiency
      标题:Synthesis Of Multifunctional Pamam-aminoglycoside Conjugates With Enhanced Transfection Efficiency
      摘要:The Development Of Multifunctional Vectors For Efficient And Safe Gene Delivery Is One Of The Major Challenges For Scientists Working In The Gene Therapy Field. In This Context,We Have Designed A Novel Type Of Aminoglycoside-Rich Dendrimers With A Defined Structure Based On Polyamidoamine (Pamam) In Order To Develop Efficient,Nontoxic Gene Delivery Vehicles. Three Different Conjugates,I.E.,Pamam G4-Neamine,-Paromomycin,And-Neomycin,Were Synthesized And Characterized By Nuclear Magnetic Resonance (NMR) And Maldi Analysis. The Conjugates Were Found To Self-Assemble Electrostatically With Plasmid Dna,And Unlike Neamine Conjugate,Each At Its Optimum Showed Increased Gene Delivery Potency Compared To Pamam G4 Dendrimer In Three Different Cell Lines,Along With Negligible Cytotoxicity. These Results All Disclosed Aminoglycosides As Suitable Functionalities For Tailoring Safe And Efficient Multifunctional Gene Delivery Vectors.
      DOI:10.1021/bc4003635

      海关参考信息

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. doi: 10.1056/NEJMoa1202657. doi: 10.1128/AAC.00628-13. Epub 2013 Jul 22.
      3: Matsushita T, Chen W, Juskeviciene R, Teo Y, Shcherbakov D, Vasella A, Böttger EC, Crich D. Influence of 4'-O-Glycoside Constitution and Configuration on Ribosomal Selectivity of Paromomycin. J Am Chem Soc. 2015 Jun 24;137(24):7706-17. doi: 10.1021/jacs.5b02248. Epub 2015 Jun 12. doi: 10.1016/j.parint.2013.07.004. Epub 2013 Jul 12. doi: 10.1016/j.tvjl.2013.05.030. Epub 2013 Jun 22. doi: 10.1371/journal.pntd.0004118. eCollection 2015.
      7: Das S, Rani M, Rabidas V, Pandey K, Sahoo GC, Das P. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. Br J Pharmacol. 2014 Mar;171(5):1260-74. doi: 10.1111/bph.12530.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知